Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Non Operating Income (2016 - 2025)

Viking Therapeutics (VKTX) has disclosed Non Operating Income for 12 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 34.61% to $7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.7 million through Dec 2025, down 17.71% year-over-year, with the annual reading at $33.7 million for FY2025, 17.71% down from the prior year.
  • Non Operating Income hit $7.1 million in Q4 2025 for Viking Therapeutics, down from $7.8 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $11.8 million in Q2 2024 to a low of $142000.0 in Q1 2022.
  • Historically, Non Operating Income has averaged $4.6 million across 5 years, with a median of $4.6 million in 2023.
  • Biggest five-year swings in Non Operating Income: plummeted 84.53% in 2021 and later skyrocketed 2168.84% in 2023.
  • Year by year, Non Operating Income stood at $154000.0 in 2021, then skyrocketed by 370.13% to $724000.0 in 2022, then skyrocketed by 546.41% to $4.7 million in 2023, then surged by 131.22% to $10.8 million in 2024, then plummeted by 34.61% to $7.1 million in 2025.
  • Business Quant data shows Non Operating Income for VKTX at $7.1 million in Q4 2025, $7.8 million in Q3 2025, and $9.0 million in Q2 2025.